Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Agilent, Synthego, Bibby Scientific, and More

NEW YORK (GenomeWeb) – Agilent Technologies announced this week that it has opened a $14.7 million, 53,000-square-foot Technology Center in Folsom, California, adjacent to its existing facility. The new building will house approximately 60 employees, and will contain a customer applications laboratory, collaboration space, and facilities for Agilent's scientific consumables and supplies. Specifically, the new facility will support Agilent's new Intuvo 9000 gas chromatography system and consumables products.

Synthego this week announced its 12 Days of CRISPR event, which includes webinars and e-learnings events for researchers and scientists interested in learning about CRISPR experiments, as well as a giveaway of $100,000 in grants and resources. Five research labs will each receive $20,000 of high-quality synthetic sgRNA for CRISPR genome editing. In order to be eligible for a prize, researchers need to demonstrate the novelty and scientific merit of their projects, the company told GenomeWeb. The institution's financial need will also be taken into account. The deadline to apply is Dec. 16.

Bibby Scientific said this week that it has taken over the distribution of Argos Technologies products in Europe, the Middle East, and Africa, starting this month. Argos products that will be available through Bibby include molecular and cell biology-related research products, as well as storage and cryo-storage equipment.

Allscripts Healthcare subsidiary 2bPrecise announced this week that Holston Medical Group will be employing the company's cloud-based genomics and precision medicine solution. The 2bPrecise EHR-agnostic solution will help HMG physicians to use genomic information to find, select, order, and receive genomic tests for their patients. The 2bPrecise solution will return results in a machine-readable and structured format, the company said.

Precision medicine company GNS Healthcare said this week that it has signed a service and license agreement with Celgene for the rights to use the GNS REFS (Reverse Engineering and Forward Simulation) causal machine learning and simulation platform for various applications, including drug discovery. Celgene has also made a second equity investment in GNS, the company noted.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.